Aspirin Resistance Reversibility in Diabetic Patients

Impact of Different Pharmacological Formulations on Aspirin Resistance Reversibility in Diabetics Patients

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01935193

Acronym

ARRDM

Enrollment

160

Registered

2013-09-05

Start date

2011-11-30

Completion date

Unknown

Last updated

2013-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aspirin Resistance

Keywords

platelets aggregation, asa resistance

Brief summary

The aim of the study is assessing the prevalence of aspirin resistance in a cohort of diabetic patients. Those found resistant has been undergone pharmacological tests using different drug formulations to investigate the reversibility of aspirin resistance.

Interventions

DRUGlysine acetylsalicylate

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* diabete mellitus type 2 * asa since 30 days at least * plts \>150000 and \<450000

Exclusion criteria

* recent ACS (within 30 days) * anticoagulant therapy * haemorragic diathesis

Design outcomes

Primary

Measure	Time frame	Description
platelets aggregation assessed by two tests (PFA100 and VerifyNow)	24 hours	diabetic patients found aspirin resistant receive and infusion of 288 mg of lysine acetylsalicylate and they are tested again 24 h after the infusion to investigate if aspirin resistance have been reversed.

Secondary

Measure	Time frame
stability of aggregation state after the reversion of aspirin resistance using oral formulation of lysine acetylsalicylate	1 month

Countries

Italy

Contacts

Primary ContactMarta Bisi, MD

martadoro@hotmail.com+393476985414

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026